Neuraxis (NRXS) Total Liabilities (2022 - 2025)
Neuraxis (NRXS) posted Total Liabilities of $3.0 million for Q4 2025, down 13.94% sequentially from $3.5 million in Q3 2025, and up 11.7% YoY from $2.7 million in Q4 2024.
Neuraxis (NRXS) Total Liabilities (2022 - 2025) Analysis & Trends
Neuraxis has reported Total Liabilities for 4 years, with the latest figure at $3.0 million in Q4 2025.
- Quarterly Total Liabilities rose 11.7% year-over-year to $3.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 million (up 11.7% YoY) and the FY2025 annual result came in at $3.0 million, up 11.7% from the prior year.
- Total Liabilities retreated to $3.0 million in Q4 2025 per NRXS's latest filing, from $3.5 million in the prior quarter.
- Over five years, Total Liabilities peaked at $11.5 million in Q2 2023 and troughed at $1.9 million in Q4 2023.
- A 4-year average of $4.4 million and a median of $3.0 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities plunged 72.89% in 2023, then soared 40.63% in 2024.
- Over 4 years, Total Liabilities stood at $7.1 million in 2022, then slumped by 72.89% to $1.9 million in 2023, then jumped by 40.63% to $2.7 million in 2024, then climbed by 11.7% to $3.0 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $3.0 million, $3.5 million, and $2.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.00 Mn |
| Sep 30, 2025 | 3.49 Mn |
| Jun 30, 2025 | 2.83 Mn |
| Mar 31, 2025 | 2.77 Mn |
| Dec 31, 2024 | 2.69 Mn |
| Sep 30, 2024 | 2.94 Mn |
| Jun 30, 2024 | 7.89 Mn |
| Mar 31, 2024 | 4.13 Mn |
| Dec 31, 2023 | 1.91 Mn |
| Sep 30, 2023 | 2.30 Mn |
| Jun 30, 2023 | 11.52 Mn |
| Dec 31, 2022 | 7.05 Mn |